Gets 4 procedural observations under Form 483
Alembic Pharmaceuticals announced that the United States Food and Drug Administration (US FDA) has completed an inspection of its general oral solid formulation facility at Panelav, Gujarat, India. This was a scheduled pre-approval inspection carried out from 22 October, 2018 to 26 October, 2018 and at the end of the inspection, the US FDA issued a Form 483 with four procedural observations.Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)